Starting treatment after surgery to help lower the chance of cancer coming back
Based on your answers, here is information about starting treatment for the first time after surgery.
Quick Links
Prepare for a conversation with your doctor
Below are some starter questions to begin a conversation with your doctor or care team:
- Can we discuss my treatment goals?
- How might adjuvant treatment help me?
- How will you know if my treatment is working?
- When will I start adjuvant treatment?

Treatment options for you
You may start treatment for the first time after surgery to help lower the chance of the cancer coming back
Your doctor may recommend one of the following:
A study examined starting treatment after surgery with PERJETA + Herceptin compared to a different treatment
Who was in the study?
4,804 people with certain types of HER2+ eBC who started treatment after surgery (adjuvant treatment).
What was the goal of the study?
To find out if people who took PERJETA + Herceptin + chemotherapy after surgery were less likely to have their cancer come back.
What were the results?
Adjuvant treatment with PERJETA + Herceptin + chemotherapy in 2,400 people lowered the risk of the cancer coming back by 18% when compared to Herceptin in 2,404 people.

Three years after starting the trial, most of the trial participants were still cancer-free, regardless of which treatment they had received. However, slightly more people in the group that had gotten PERJETA + Herceptin + chemotherapy were cancer-free (94.1%), compared with the other group (93.2%).
What are the most serious side effects of PERJETA?
- PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).
- Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.
What are other possible serious side effects of PERJETA?
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA. Possible serious and sometimes fatal side effects of PERJETA include infusion-related reactions and severe allergic reactions (hypersensitivity reactions/anaphylaxis).
See additional Important Safety Information below.
If your doctor recommends PERJETA + Herceptin after surgery

PERJETA + Herceptin treatment is up to 18 cycles in total (about 1 year) unless the cancer comes back sooner or side effects require the treatment to stop.
Discover study results with PHESGO
- See clinical trial results
- Find out if more people preferred PHESGO or PERJETA + Herceptin
If your doctor recommends PHESGO after surgery

PHESGO treatment is up to 18 cycles in total (about 1 year) unless the cancer comes back sooner or requires the treatment to stop.
Summarizing the key differences between these two treatments
PERJETA + Herceptin | PHESGO | |
---|---|---|
Active ingredients | pertuzumab trastuzumab | pertuzumab trastuzumab hyaluronidase |
Administration method | Intravenous (IV) infusion, given by a care provider | Subcutaneous (under the skin) injection, given by a care provider |
Administration time | About 1-2.5 hours*:
|
Your first dose is given in about 8 minutes. Other injections take about 5 minutes.* |
Study results summary | A study comparing PHESGO to PERJETA + Herceptin found no major difference is expected in how well PHESGO works. By taking PHESGO, you’re taking the same medicines, just in less time. There are side effects associated with both treatments. The comparison study did not find any significant difference between the 2 treatments. |
*This does not account for observation time and other aspects of treatment. Actual clinic time may vary.
Keep in mind that this site is for educational purposes only and that the options here are just some of the treatments you may be eligible for. Your primary sources of information should always be your doctor and the professionals who make up your care team. Only they can give you medical advice about your disease and treatment.